Alis Biosciences says its goal is to return to investors billions of dollars stuck on the balance sheets of “moribund” ...

In recent weeks, biotech companies have faced setbacks in moving forward with clinical trials due to operational delays at the FDA, according to an exclusive report from The Wall Street Journal ...